SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Akari Therapeutics Plc

(Name of Issuer)

Ordinary shares, $0.000000005 par value

(Title of Class of Securities)

03/02/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP Number(s):

Names of Reporting Persons

Hoyoung Huh, M.D., Ph.D.

Check the appropriate box if a member of a Group (see instructions)

(a)

(b)

Sec Use Only

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 18,199,697,667.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 18,199,697,667.00
8	Shared Dispositive Power 0.00

Aggregate Amount Beneficially Owned by Each Reporting Person

18,199,697,667.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in row (9)

18.4 %

Type of Reporting Person (See Instructions)

Comment for Type of Reporting Person: 1) Comprised of the Registrant's ordinary shares, $0.000000005 par value per share ("Ordinary Shares"), represented by American Depositary Shares ("ADSs"). Each ADS represents 2,000 Ordinary Shares. (2) Includes (i) 9,391,708,000 shares held of record by Reporting Person, (ii) 1,061,691,667 shares underlying options exercisable within 60 days of March 1, 2026 granted to Reporting Person, (iii) 103,482,000 shares underlying warrants exercisable within 60 days of March 1, 2026 (iv) 7,423,902,000 shares underlying prefunded warrants exercisable within 60 days of March 1, 2026, and (v) 218,914,000 shares held of record by Hannol Ventures LLC. Excludes up to 10,995,330,000 shares underlying warrants exercisable within 60 days of March 1, 2026 issued to Reporting Person which are subject to a 9.99% beneficial ownership limitation and with respect to which Reporting Person disclaims beneficial ownership to the extent that any exercise of such warrants would exceed such percentage. (3) The percentage of ownership is based on 91,567,009,533 ordinary shares issued and outstanding on March 1, 2026, as per information provided to the Reporting Person by the Issuer.

SCHEDULE 13G

Item 1.

(a)

Name of issuer:

Akari Therapeutics Plc

(b)

Address of issuer's principal executive offices:

401 East Jackson Street, Suite 3300, Tampa, FL 33602

Item 2.

(a)

Name of person filing:

Hoyoung Huh, M.D., Ph.D.

(b)

Address or principal business office or, if none, residence:

c/o Akari Therapeutics Plc 401 East Jackson Street, Suite 3300, Tampa, FL 33602

(c)

Citizenship:

U.S.

(d)

Title of class of securities:

Ordinary shares, $0.000000005 par value

(e)

CUSIP No.:

00972G207

Item 3.

If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a)

Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

(b)

Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

(c)

Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

(d)

Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

(e)

An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f)

An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g)

A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h)

A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i)

A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j)

A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:

(k)

Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

Item 4.

Ownership

(a)

Amount beneficially owned:

18,199,697,667

(b)

Percent of class:

18.4%

(c)

Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

18,199,697,667

(ii) Shared power to vote or to direct the vote:

(iii) Sole power to dispose or to direct the disposition of:

18,199,697,667

(iv) Shared power to dispose or to direct the disposition of:

Item 5.

Ownership of 5 Percent or Less of a Class.

Not Applicable

Item 6.

Ownership of more than 5 Percent on Behalf of Another Person.

Not Applicable

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable

Item 8.

Identification and Classification of Members of the Group.

Not Applicable

Item 9.

Notice of Dissolution of Group.

Not Applicable

Item 10.

Certifications:

Not Applicable

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Hoyoung Huh, M.D., Ph.D.

Signature:	/s/ Hoyoung Huh, M.D., Ph.D.
Name/Title:	Hoyoung Huh, Authorized Person
Date:	03/04/2026

Amendment: SEC Form SCHEDULE 13G/A filed by Akari Therapeutics plc